#ESMO26 Can sacituzumab tirumotecan + pembrolizumab deliver durable responses? Updated phase II results in cisplatin-ineligible, previously untreated advanced/mUC (N=40).
🔹 Confirmed ORR: 68%; DCR: 88%
🔹 Median DOR: 19.4 months
🔹 Median PFS: 11.2 months; OS not reached
🔹 Responses observed across TROP2 and PD-L1 expression subgroups, although numbers were small.
🔹 Grade 3–4 TRAEs: 65% (4 mg/kg) vs 57% (5 mg/kg)
@UroToday @myESMO
32 浏览 · 1 赞 · 2 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com